- Home
- IDYA vs SPHR Comparison
IDYA vs SPHR Comparison
Compare IDYA & SPHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IDYA
- SPHR
- Stock Information
- Founded
- IDYA 2015
- SPHR 2020
- Country
- IDYA United States
- SPHR United States
- Employees
- IDYA N/A
- SPHR N/A
- Industry
- IDYA Biotechnology: Pharmaceutical Preparations
- SPHR Services-Misc. Amusement & Recreation
- Sector
- IDYA Health Care
- SPHR Consumer Discretionary
- Exchange
- IDYA Nasdaq
- SPHR Nasdaq
- Market Cap
- IDYA 2.3B
- SPHR 2.1B
- IPO Year
- IDYA 2019
- SPHR N/A
- Fundamental
- Price
- IDYA $31.60
- SPHR $67.40
- Analyst Decision
- IDYA Buy
- SPHR Buy
- Analyst Count
- IDYA 17
- SPHR 8
- Target Price
- IDYA $48.20
- SPHR $55.13
- AVG Volume (30 Days)
- IDYA 1.3M
- SPHR 932.3K
- Earning Date
- IDYA 11-04-2025
- SPHR 11-11-2025
- Dividend Yield
- IDYA N/A
- SPHR N/A
- EPS Growth
- IDYA N/A
- SPHR N/A
- EPS
- IDYA N/A
- SPHR N/A
- Revenue
- IDYA $7,000,000.00
- SPHR $1,040,932,000.00
- Revenue This Year
- IDYA $90.17
- SPHR $10.41
- Revenue Next Year
- IDYA $219.42
- SPHR $9.71
- P/E Ratio
- IDYA N/A
- SPHR N/A
- Revenue Growth
- IDYA N/A
- SPHR 1.37
- 52 Week Low
- IDYA $13.45
- SPHR $23.89
- 52 Week High
- IDYA $33.64
- SPHR $69.98
- Technical
- Relative Strength Index (RSI)
- IDYA 63.75
- SPHR 65.01
- Support Level
- IDYA $28.17
- SPHR $62.08
- Resistance Level
- IDYA $33.64
- SPHR $69.98
- Average True Range (ATR)
- IDYA 1.70
- SPHR 2.91
- MACD
- IDYA 0.33
- SPHR 0.15
- Stochastic Oscillator
- IDYA 72.58
- SPHR 78.14
About IDYA IDEAYA Biosciences Inc.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.
About SPHR Sphere Entertainment Co.
Sphere Entertainment Co is a live entertainment and media company. The firm creates, writes, casts, produces, and tours shows and events. The group has two reportable segments which includeSphere and MSG Networks. Sphere is a next-generation entertainment medium, and MSG Networks operates two regional sports and entertainment networks, as well as a direct-to-consumer (DTC) and authenticated streaming product.